SKYE vs. GLSI, SCPH, AEON, CAPR, CRVO, PRQR, IVA, GOSS, ANVS, and ACET
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Greenwich LifeSciences (GLSI), scPharmaceuticals (SCPH), AEON Biopharma (AEON), Capricor Therapeutics (CAPR), CervoMed (CRVO), ProQR Therapeutics (PRQR), Inventiva (IVA), Gossamer Bio (GOSS), Annovis Bio (ANVS), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Greenwich LifeSciences (NASDAQ:GLSI) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
Greenwich LifeSciences has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
Greenwich LifeSciences currently has a consensus price target of $36.00, suggesting a potential upside of 185.71%. Skye Bioscience has a consensus price target of $22.50, suggesting a potential upside of 73.08%. Given Skye Bioscience's higher probable upside, equities research analysts plainly believe Greenwich LifeSciences is more favorable than Skye Bioscience.
Greenwich LifeSciences received 4 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 52.9% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Greenwich LifeSciences had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Greenwich LifeSciences and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.03 beat Greenwich LifeSciences' score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Greenwich LifeSciences' return on equity of 0.00% beat Skye Bioscience's return on equity.
Summary
Greenwich LifeSciences beats Skye Bioscience on 8 of the 14 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
